拉丁美洲慢性髓性白血病无治疗缓解推荐:LALNET专家共识
拉丁美洲CML专家工作组讨论22个TFR相关问题并达成共识,提出在临床试验外停用TKI的推荐。TFR适用于第一慢性期、典型BCR-ABL转录本、TKI治疗至少5年且持续DMR(MR4.5)2年者,需至少4次间隔≥3个月的国际标准定量PCR证实。停药后需规范分子监测并管理撤药综合征、血糖和血脂。
要点
- TFR适用于第一慢性期、典型BCR-ABL、TKI≥5年且MR4.5持续2年者。
- 既往不耐受而非耐药者二线治疗后也可考虑TFR。
- 停药后前6个月每月监测BCR-ABL,丧失MMR即重启治疗。
核心结论
- 在拉丁美洲地区,符合特定条件的CML患者可在临床试验外安全尝试TKI停药以实现TFR。
研究设计与样本
- 拉丁美洲CML专家工作组讨论22个TFR相关问题并达成区域共识推荐。
主要发现
- TFR适用于第一慢性期、典型BCR-ABL转录本、TKI治疗至少5年、MR4.5持续2年者。
- 持续DMR需在近2年内至少4次国际标准定量PCR证实,间隔至少3个月。
- 二线治疗后TFR适用于既往不耐受而非耐药的患者。
关键数值与推荐
- TKI治疗最短5年,MR4.5持续2年,近2年至少4次PCR间隔≥3个月。
- 停药后前6个月每月分子监测,第7至12个月每2至3个月,第2年每3个月,之后无限期。
- 丧失MMR时应重新开始治疗。
- 停药后建议监测撤药综合征、血糖水平和血脂谱。
- TKI再治疗后每2至3个月监测直至达MR4.0,之后每3至6个月。
临床怎么用
- 尝试TFR前必须确保BCR-ABL PCR检测标准化且可靠。
- 按推荐频率进行分子监测,丧失MMR即重启TKI治疗。
- 停药后需监测撤药综合征、血糖和血脂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tyrosine kinase inhibitors (TKIs) have dramatically changed the survival of chronic myeloid leukemia (CML) patients, and treatment-free remission (TFR) has recently emerged as a new goal of CML treatment. The aim of this work was to develop recommendations for TKI discontinuation in Latin America (LA), outside of clinical trials. A working group of CML experts from LA discussed 22 questions regarding TFR and reached a consensus for TFR recommendations in the region. TFR is indicated in patients in first chronic phase, with typical BCR-ABL transcripts, under TKI treatment of a minimum of 5 years, in sustained deep molecular response (DMR; molecular response 4.5 [MR4.5]) for 2 years. Sustained DMR must be demonstrated on at least 4 international reporting scale quantitative polymerase chain reaction (PCR) tests, separated by at least 3 months, in the immediate prior 2 years. After second-line therapy, TFR is indicated in previously intolerant, not resistant, patients. Molecular monitoring is recommended monthly for the first 6 months, every 2 to 3 months from months 7 to 12, and every 3 months during the second year, indefinitely. Treatment should be reintroduced if major molecular response is lost. Monitoring of withdrawal syndrome, glucose levels, and lipid profile is recommended after discontinuation. After TKI reintroduction, molecular monitoring is indicated every 2 to 3 months until MR4.0 achievement; later, every 3 to 6 months. For the TFR attempt, having standardized and reliable BCR-ABL PCR tests is mandatory. These recommendations will be useful for safe discontinuation in daily practice and will benefit patients who wish to stop treatment in emergent regions, in particular, with TKI-related chronic adverse events.
引用
- Pavlovsky C, Abello Polo V, Pagnano K, et al. Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel. Blood Adv. 2021. PMID: 34438444. doi:10.1182/bloodadvances.2020003235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。